Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evaluation of the safety profile of COVID-19 vaccines: a rapid review
Qianhui Wu, Matthew Z. Dudley, Xinghui Chen, et al.
BMC Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 215

Showing 1-25 of 215 citing articles:

Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
Pedro Machado, Saskia Lawson‐Tovey, Anja Strangfeld, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 5, pp. 695-709
Open Access | Times Cited: 167
Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong
Francisco Tsz Tsun Lai, Lei Huang, Celine Sze Ling Chui, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 77
COVID-19 vaccines adverse events: potential molecular mechanisms
Malamatenia Lamprinou, Athanasios Sachinidis, Εleni Stamoula, et al.
Immunologic Research (2023) Vol. 71, Iss. 3, pp. 356-372
Open Access | Times Cited: 64
Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study
Haya Omeish, Angam Najadat, Sayer Al‐Azzam, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 82
Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional Study
Chenyuan Qin, Ruitong Wang, Liyuan Tao, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 89-89
Open Access | Times Cited: 68
Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran
Hamed Zare, Hadis Rezapour, Sara Mahmoodzadeh, et al.
International Immunopharmacology (2021) Vol. 101, pp. 108351-108351
Open Access | Times Cited: 57
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
Kimberly A. Kraynyak, Elliott Blackwood, Joseph Agnes, et al.
The Journal of Infectious Diseases (2022) Vol. 225, Iss. 11, pp. 1923-1932
Open Access | Times Cited: 47
Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms
Ameneh Jafari, Fahima Danesh Pouya, Zahra Niknam, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 6, pp. 4943-4957
Open Access | Times Cited: 41
COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic
Aleksandra Anna Zasada, Aniela Darlińska, Aldona Wiatrzyk, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1786-1786
Open Access | Times Cited: 23
Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study
Majid Eterafi, Nasrin Fouladi, Majid Golizadeh, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0296669-e0296669
Open Access | Times Cited: 9
Oral lichen planus following the administration of vector‐based COVID‐19 vaccine (Ad26.COV2.S)
Matthias Troeltzsch, Markus Gogl, Ronald Berndt, et al.
Oral Diseases (2021) Vol. 28, Iss. S2, pp. 2595-2596
Open Access | Times Cited: 47
COVID-19 Vaccines: Current and Future Perspectives
Luca Soraci, Fabrizia Lattanzio, Giulia Soraci, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 608-608
Open Access | Times Cited: 37
Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study
Carlos King Ho Wong, Kristy T. K. Lau, Xi Xiong, et al.
PLoS Medicine (2022) Vol. 19, Iss. 6, pp. e1004018-e1004018
Open Access | Times Cited: 34
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
Saskia Räuber, Melanie Korsen, Niklas Huntemann, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 93, Iss. 9, pp. 978-985
Open Access | Times Cited: 29
Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study
Mona Sadat Larijani, Rahim Sorouri, Sana Eybpoosh, et al.
Pathogens and Disease (2023) Vol. 81
Closed Access | Times Cited: 19
Real-World Safety of COVID-19 mRNA Vaccines: A Systematic Review and Meta-Analysis
Wanqian Xu, Weigang Ren, Tongxin Wu, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1118-1118
Open Access | Times Cited: 18
From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era
Ganggang Miao, Zhiqiang Chen, Hengsong Cao, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 158, pp. 114208-114208
Open Access | Times Cited: 17
Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis
Anastasia Phillips, Yannan Jiang, Donna Walsh, et al.
Vaccine (2023) Vol. 41, Iss. 42, pp. 6227-6238
Open Access | Times Cited: 17
Rapid reviews methods series: assessing the appropriateness of conducting a rapid review
Chantelle Garritty, Barbara Nußbaumer-Streit, Candyce Hamel, et al.
BMJ evidence-based medicine (2024), pp. bmjebm-112722
Open Access | Times Cited: 8
Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
Rima Moghnieh, Rana Mekdashi, Salam El-Hassan, et al.
Vaccine (2021) Vol. 39, Iss. 46, pp. 6713-6719
Open Access | Times Cited: 38
Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials
Jiaxin Chen, Yuangui Cai, Yicong Chen, et al.
Vaccines (2021) Vol. 9, Iss. 8, pp. 939-939
Open Access | Times Cited: 33
Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines in Rheumatic Patients: An Updated Systematic Review and Meta-Analysis
Kuo‐Tung Tang, Bo‐Chueh Hsu, Der‐Yuan Chen
Biomedicines (2022) Vol. 10, Iss. 4, pp. 834-834
Open Access | Times Cited: 28
Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
Walter L. Straus, Verónica Urdaneta, Daina B. Esposito, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e544-e552
Open Access | Times Cited: 27
Effectiveness and Safety of COVID-19 Vaccinations: An Umbrella Meta-Analysis
Zhu Liduzi Jiesisibieke, Wenyi Liu, Yupei Yang, et al.
International Journal of Public Health (2023) Vol. 68
Open Access | Times Cited: 16
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
Eline A. Feitsma, Yester F. Janssen, Hendrikus H. Boersma, et al.
Vaccine (2023) Vol. 41, Iss. 13, pp. 2184-2197
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top